Drugs / OL-108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06980597 | Jun 2025 → Dec 2027 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathy, systemic lupus erythematosus, systemic sclerosis | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OL-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06980597 ↗ |
| Modality | Cell therapy | “Allogeneic CAR-T Cell Therapy (OL-108)” NCT06980597 ↗ |
| Route | Intravenous | “OL-108 will be given through IV bolus” NCT06980597 ↗ |